|
I'll put her on http://www.vendre-une-voiture.fr/blissby-b6d4.pdf#revive blissby In the earlier trials of solanezumab, there were not enough patients with mild Alzheimer's and amyloid to confirm the effectiveness of the drug, Siemers said. But there were indications that it worked in this group. More than a third showed slower cognitive decline when they took the drug, compared to a placebo, and there was some indication that their functional abilities improved as well, he said.
|